Stock Price & Analysis

-
$
0.000
0.000(0%)6M

GRFS Stock Price Chart

5D
1M
3M
6M
YTD
1Y
5Y

GRFS Fundamental Analysis

buy
Moderate Buy
Buy
Hold
Sell
bubble
High
bubble
Averages
bubble
Low
Analyst
Rating
Action
Price Target
Date
Rating Reason
Deutsche Bank
Emmanuel Papadakis
Hold
Strong Sell
Downgrades
n/a
2024-03-12
JP Morgan
James Quigley
Hold
Maintains
$10 → $11
2023-12-05
Deutsche Bank
Emmanuel Papadakis
Strong Buy
Hold
Downgrades
n/a
2021-11-05
Credit Suisse
Trung Huynh
Hold
Buy
Upgrades
n/a
2021-03-23
HSBC
Steve McGarry
Hold
Strong Buy
Upgrades
n/a
2021-03-11

GRFS Earnings Analysis

Grifols, S.A. Corporation (GRFS.O) Q3 2023 Earnings Conference Call

Positive

  • Revenue growth has been consistently strong, with 8.4% growth for the first 9 months of the year and revenues exceeding €4.8 billion at constant currency. Biopharma and key proteins were major contributors to this growth, with a notable performance in immunoglobulin and albumin franchises.

  • Revenue grew 9.1% in Q1, 6.5% in Q2, and 9.6% in Q3 at constant currency.

  • Biopharma performance was robust with immunoglobulin sales growing by 17.4% in Q3 and 15% year-to-date at constant currency.

  • Albumin franchise saw a revenue increase of close to 18% year-to-date due to higher demand in China and solid price increases in key markets.

  • The company achieved a 25.1% adjusted EBITDA margin in Q3, representing a significant improvement of 480 basis points compared to Q4 '22 margin. The strong revenue growth, operational improvement plan execution, and cost savings led to enhanced profitability.

  • Operational improvement plan drove revenue and margin expansion, contributing to the improved EBITDA margin.

  • Cost per liter reduced by 22% since July 2022 peak, leading to margin expansion.

  • Commitment to achieve higher end of EBITDA guidance with an anticipated margin increase to 28-29% in line with 2019 levels.

  • Grifols has made substantial progress on its deleveraging path, with the leverage ratio decreasing to 6.7x at the end of September 2023 from a peak of 9x last year. The company remains confident in reaching the 4x leverage target by the end of 2024 with a focus on executing a deleveraging transaction and strengthening the balance sheet.

  • Strong organic efforts and improved profitability contributed to deleveraging progress.

  • Liquidity exceeding €1 billion, including €454 million in cash, provides a strong financial position.

  • Focus on operational efficiencies, cost savings, and operating cash flow improvement to support deleveraging goals.

Negative

  • Revenue growth in the Diagnostic segment declined by 3.1% in the quarter, impacting overall performance negatively.
  • Bio Supplies revenues declined by 14.1% due to lower cell culture sales, indicating subdued demand.
  • Despite strong profitability, the leverage ratio decreased to 6.7x but still falls short of the target of 4x by 2024.

GRFS News

bubble
6.0
03-10Business Insider
Grifols price target raised to EUR 11 from EUR 10 at Deutsche Bank
bubble
7.0
02-27Business Insider
Grifols sees reaching EUR 10B in revenue by 2029
bubble
7.0
02-27Business Insider
Grifols sees 2025 revenue EUR 7.7B, EBITDA above EUR 2B
bubble
9.5
02-26Business Insider
Grifols reports Q4 adjusted EBITDA of EUR 526M, up 19% from last year
bubble
4.0
02-14Business Insider
Grifols price target lowered to EUR 15.25 from EUR 15.40 at Berenberg

GRFS FAQs

What is surpport and resistant level for GRFS Stock?

The S1 support level for GRFS Stock is $7.55 ,The R1 resistant level for GRFS Stock is $8.66.

What is the current price of GRFS Stock?

What is the market cap of Grifols SA?

What is Grifols SA (GRFS)'s business?

How many employees does GRFS have?

GRFS Key Stats

High
7.990
Vol
516.97K
Low
7.860
Amount
4.10M
Open
7.900
VWAP
7.93
Mkt Cap
5.49B
EV/EBITDA(TTM)
10.36

GRFS Company Profile

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.